Bausch + Lomb Corp (BLCO) FinancialsBLCOBausch + Lomb Corp

Bausch + Lomb Corp (BLCO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Devices, accounting for 37.6% of total sales, equivalent to $524.00M. Other significant revenue streams include OTC and Pharmaceuticals. Understanding this composition is critical for investors evaluating how BLCO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Bausch + Lomb Corp maintains a gross margin of 58.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.75%, while the net margin is -0.72%. These profitability ratios, combined with a Return on Equity (ROE) of -2.67%, provide a clear picture of how effectively BLCO converts its operational activities into shareholder value.

In the context of the broader market, BLCO competes directly with industry leaders such as TFX and STVN. With a market capitalization of $6.12B, it holds a leading position in the sector. When comparing efficiency, BLCO's gross margin of 58.11% stands against TFX's 58.16% and STVN's 29.51%. Such benchmarking helps identify whether Bausch + Lomb Corp is trading at a premium or discount relative to its financial performance.

Bausch + Lomb reported Q2 2026 revenue of $1.39 billion, showing a year-over-year growth of 8%. The gross margin has improved to 58.11%, reflecting better cost management and profitability.